Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals (ALNY) sees mixed social sentiment as positive clinical trial data for Vutrisiran and strong Amvuttra sales are countered by negative sentiment on X and FDA advertising concerns.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics.
Alnylam Pharmaceuticals, Inc. uses the ticker $ALNY for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Alnylam Pharmaceuticals, Inc. (ALNY) social dominance is up 424.59% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) sentiment is up 42.86% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) creators is up 20.89% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) engagements is up 242.7% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) mentions is up 32.66% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) posts created is up 176% from the previous week.
Price: $314.40
Price 24-Hour Time-Series Raw Data
The stock price is experiencing volatility, with positive clinical trial data and strong sales being offset by regulatory concerns and negative social media sentiment, leading to a balanced outlook.
24-Hour: 3.92% 7-Day: -4% 30-Day: -12.49%
1-Year High: $491.20 on 2025-10-20
1-Year Low: $224.30 on 2025-04-08
AltRank: [---]
AltRank 24-Hour Time-Series Raw Data
Alnylam Pharmaceuticals, Inc. (ALNY) is currently AltRank #992 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [---] +115
[--] Month: [---] +256
[--] Months: [---] +616
[--] Year: [---] +395
1-Year High: [-----] on 2025-06-08
1-Year Low: [--] on 2025-03-22
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2026-01-01
1-Year Low: [--] on 2025-06-26
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [-------] +243%
[--] Month: [-------] -42%
[--] Months: [---------] -26%
[--] Year: [---------] -22%
1-Year High: [-------] on 2025-03-21
1-Year Low: [-----] on 2026-02-01
Engagements by network (24h): Reddit: [--] News: [--] X: [-----] YouTube: [--]
Mentions: [---] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
[--] Week: [---] +33%
[--] Month: [---] +1.70%
[--] Months: [-----] -30%
[--] Year: [-----] -15%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-12-07
Mentions by network (24h): Reddit: [--] News: [--] X: [---] YouTube: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Alnylam Pharmaceuticals, Inc. (ALNY) in the last [--] hours which is down 10% from [--] in the previous [--] hours
Daily Average: [---]
[--] Week: [---] +21%
[--] Month: [---] +10%
[--] Months: [-----] -41%
[--] Year: [-----] +54%
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-12-07
The most influential creators that mention Alnylam Pharmaceuticals, Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @GeneInvesting | [--] | [------] | [--] | [---] |
| @earnings_guy | [--] | [------] | [--] | [---] |
| @Andre_AGTC | [--] | [-----] | [--] | [---] |
| @RNAiAnalyst | [--] | [------] | [--] | [---] |
| @BosBizJournal | [--] | [------] | [--] | [---] |
| @Tickeron | [--] | [------] | [--] | [---] |
| @AnitaMc26910087 | [--] | [---] | [--] | [--] |
| @MarcJacksonLA | [--] | [-----] | [--] | [--] |
| @TTRAmyloid | [--] | [-----] | [--] | [--] |
| @adamfeuerstein | [--] | [-------] | [--] | [--] |
Sentiment: 75%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 75%
Daily Average: 67%
[--] Week: 100% +30%
[--] Month: 71% +2%
[--] Months: 71% -7%
[--] Year: 71% +13%
1-Year High: 100% on 2025-07-29
1-Year Low: 26% on 2025-12-02
Most Supportive Themes:
- Positive Data from HELIOS-B Study: (35%) New data from the HELIOS-B Phase [--] study shows reduced gastrointestinal events in ATTR-CM patients treated with Vutrisiran, supporting its use as a first-line therapy.
- Amvuttra Sales and Revenue Guidance: (20%) Alnylam reported strong Amvuttra sales and increased its [----] revenue guidance, indicating positive financial performance.
- First Patient Dosed in ZENITH Trial: (15%) Alnylam announced the first patient has been dosed in the ZENITH Global Phase [--] cardiovascular outcomes trial of Zilebesiran, marking progress in its clinical pipeline.
Most Critical Themes:
- Negative Sentiment on X: (20%) A significant portion of posts on X express negative sentiment, with users raising concerns about the company.
- FDA Crackdown and Ad Pull: (10%) Alnylam has withdrawn TV advertisements following regulatory action on drug industry advertising, which may lead to concerns.
Social Dominance: 0.00977%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00977%
Daily Average: 0.025%
[--] Week: 0.032% +0.026%
[--] Month: 0.012% -0.011%
[--] Months: 0.012% -0.029%
[--] Year: 0.012% -0.022%
1-Year High: 0.065% on 2025-03-24
1-Year Low: 0.0055% on 2025-12-07
Market Dominance: 0.047%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.047%
Daily Average: 1%
1-Year High: 2.10% on 2025-12-02
1-Year Low: 0.047% on 2026-02-16
Market Cap: $41,536,584,379
Market Cap 24-Hour Time-Series Raw Data
Current Value: $41,536,584,379
Daily Average: $47,098,517,360
[--] Week: $41,696,716,474 -2.40%
[--] Month: $41,696,716,474 -12%
[--] Months: $41,696,716,474 -31%
[--] Year: $41,696,716,474 +26%
1-Year High: $64,388,633,748 on 2025-10-20
1-Year Low: $29,032,966,164 on 2025-04-08
Top Alnylam Pharmaceuticals, Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$VRTX vs $REGN vs $ALNY Stock Comparison: Earnings Recap as Vertexs Steady CF Engine Meets Regenerons EYLEA Test and Alnylams Profit Breakthrough $CRSP $NTLA $VKTX $BEAM $INCY $BMRN https://tickeron.com/pick-the-best/ALNY-or-REGN-or-VRTX/ https://tickeron.com/pick-the-best/ALNY-or-REGN-or-VRTX/"
X Link @Tickeron 2026-02-16T11:40Z 19.3K followers, [---] engagements
"As was promised at the start of [----] Alnylam Pharmaceuticals Inc. has become a profitable company following the approval of its rare heart-disease drug. https://www.bizjournals.com/boston/news/2026/02/12/alnylam-becomes-profitable.htmlcsrc=6398&taid=6992cb06c4c82c00019f5066&utm_campaign=trueAnthemTrendingContent&utm_medium=social&utm_source=twitter https://www.bizjournals.com/boston/news/2026/02/12/alnylam-becomes-profitable.htmlcsrc=6398&taid=6992cb06c4c82c00019f5066&utm_campaign=trueAnthemTrendingContent&utm_medium=social&utm_source=twitter"
X Link @BosBizJournal 2026-02-16T07:45Z 73.6K followers, [---] engagements
"$CMG $CAG $DOW $ALNY $PTHL $ORIS $OST $INTU $GERN $ENPH $GIS $OSRH $TSLA $PLTR $RKLB $LCID $SXTC $GXAI $LICN $BABA $SATL $SGMO $AMD $DJT $AAPL #_"
X Link @retaal1932 2026-02-15T21:43Z [--] followers, [---] engagements
"$BBIO at the risk of waxing grandiloquent myself: Im proud to be a part-owner of $BBIO a david whos had to overcome multiple Goliaths. The entrenched institutional darlings in ATTR-CM $ALNY who for a while could do no wrong. (and $PFE menacing) And now those same counterparts in Achondroplasia $ASND $BMRN. acoramidis survived its odyssey and thrives infigratinib will as well: https://twitter.com/i/web/status/2023088061261709411 https://twitter.com/i/web/status/2023088061261709411"
X Link @PersimmonTI 2026-02-15T17:32Z 10.9K followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing